Skip to main
ENLV

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Therapeutics Ltd has established a robust financial strategy with its existing at-the-market (ATM) facility, enabling the company to capitalize on its elevated trading volume to enhance liquidity for its lead immunotherapy product, Allocetra. The recent Phase IIa trial results revealed statistically significant improvements in pain reduction and functional outcomes, particularly in older patients with idiopathic age-related osteoarthritis, a substantial segment of the osteoarthritis market. Furthermore, the company's ongoing efforts in strengthening its intellectual property portfolio, including a patent application for Allocetra in osteoarthritis, further bolster its competitive positioning and growth prospects in the biopharmaceutical sector.

Bears say

Enlivex Therapeutics faces uncertainty surrounding its recent strategic pivot, leading to concerns about the implications for its capital access and investor engagement. The company appears to struggle with a disconnect between its clinical advancements and market recognition, which could hinder its ability to attract investment. Additionally, while there are potential benefits in the KOA program if data proves consistent, the overall lack of clarity and confidence in these developments contributes to a negative outlook for the company's stock.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.